KORU Medical Systems, Inc. Q2 2026 Earnings Call Summary
KORU Medical Systems reported Q2 2026 revenue up 18% and first positive net income since 2019, with domestic revenue up 12% and international revenue up 59%. It withdrew a US FDA 510(k) for Phesgo, narrowed FY revenue guidance to $47.5M-$48.5M, raised gross margin to 62%-64%, and expects positive adjusted EBITDA in 2026.
How this was made
The 30-second read
Why it matters
Traders can update models around FY 2026 revenue and gross margin ranges, cash runway assumptions, and the timing of key regulatory and product milestones (Freedom360 510(k) targeted end-2027).
Market read
The call includes multiple forward-looking, decision-relevant disclosures: FY revenue and gross margin guidance ranges, cash balance target, and regulatory/product timing changes.
What to watch
International non-tender growth is described as a 12-18 month conversion ramp, so near-term revenue volatility could persist despite narrowed guidance; also, the Biogen-Apellis acquisition could disrupt trial timing.
Background
This is a Q2 2026 earnings call summary for KORU Medical Systems, covering performance attribution, guidance, regulatory strategy, and pipeline/commercial milestones.
Ticker impact
KORU reported Q2 revenue +18%, first positive net income since 2019, and narrowed FY revenue guidance to $47.5M-$48.5M.
Likely positive bias for near-term trading on profitability progress and improved margin outlook, partially offset by Phesgo US withdrawal and Pharma Services timing variability.
The article provides multiple concrete forward-looking datapoints (revenue range, gross margin range, cash balance target, 510(k) withdrawal, and 2027 pump submission timing) that can reprice expectations, but it is a call summary rather than a primary filing and lacks consensus/market reaction context.
Market effects
Highlights execution risk and margin sensitivity in immunoglobulin and oncology biologics commercialization, plus growing importance of connected monitoring and real-world evidence.
Emphasizes Europe distributor-led conversions for prefilled syringe formats, implying near-term US oncology exposure reduction.
Limited direct global macro linkage; more relevant to specialty pharma commercialization and clinical trial services workflows.
Counterpoint
The Phesgo US 510(k) withdrawal and Pharma Services revenue decline suggest underlying demand or regulatory attractiveness may be weaker than the profitability narrative implies.
Key entities
- companyKORU Medical Systems, Inc.
Reported Q2 growth and profitability milestone, narrowed FY revenue guidance, raised gross margin guidance, withdrew US FDA 510(k) for Phesgo, and discussed Freedom/Freedom360 and connected monitoring acquisition.
- productPhesgo
KORU withdrew its US FDA 510(k) application, pivoting domestic oncology strategy toward other biologics while keeping international opportunity active.
- productFreedom360
Next-generation pump with US 510(k) submission targeted for end-2027 after high-risk development stages.
- companyApellis
Mentioned as being acquired by Biogen, potentially affecting near-term clinical trial activity timing.